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Introduction: Young cancer patients increasingly request fertility sparing alternatives to their cancer treatments,
which they should be offered when allowed so by the risk-benefit balance and after obtaining informed consent.
Case presentation: Here, we report the case of a 25 year-old nulliparous patient who presented with a
synchronous endometrioid ovarian and endometrial carcinoma. She was able to conduct a full-term spontaneous
pregnancy after conservative surgical treatment followed by adjuvant chemotherapy and hormonal treatment.
Fertility sparing treatment is feasible in selected cases of synchronous ovarian and endometrial cancers. Thorough
follow-up remains mandatory.
Conclusion: This case demonstrates some interesting and unique features of synchronous ovarian and endometrial
cancers since it resulted in a spontaneous pregnancy and normal delivery.
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The gynecologic oncologist is in a unique position to
provide young gynecologic cancer patients with fertility-
sparing surgical alternatives when allowed so by tumor
stage and histologic differentiation, while still offering the
best curative treatment. Fertility sparing surgery for epi-
thelial ovarian cancer as well as endometrial carcinoma
has been abundantly described in the literature, in small
series and retrospective cohorts [1-4]. The synchronous
occurrence of both tumors, especially in young patients, is
equally well-reported [5,6]. The conservative management
of early ovarian and endometrial cancer is possible in certain
histologic profiles. This is followed by a spontaneous preg-
nancy and normal delivery. To date, our own search in the
English literature revealed that our case is the first reported
one of conservatively treated synchronous endometrial and
ovarian cancer followed by a successful pregnancy.* Correspondence: david.atallah@gmail.com
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A 25 year-old nulliparous woman was addressed to our
center, Hôtel Dieu de France University Hospital, few weeks
after being operated by laparoscopy of an 11 cm ruptured
left adnexal cystic mass on May 2010. Pathology results
showed an endometrioid grade I ovarian adenocarcinoma.
She was subsequently scheduled for a conservative sur-
gery that included a total abdominopelvic exploration, left
adnexectomy, peritoneal washings, random biopsies, infra-
gastric omentectomy, resection of trocars insertion sites
and bilateral ilio-obturator as well as para-aortic lymph
node dissection reaching the left renal vein. An endometrial
curettage was also carried out and later showed a well-
differenciated endometrioid adenocarcinoma with com-
plex hyperplasia. A frozen section at the time of surgery
confirmed the absence of residual proliferating or viable
tumoral cells in the left ovary with only necrotic granu-
lomatous material left. Peritoneal cytology, omentectomy,
lymph nodes (26 pelvic and 17 para-aortic) and trocar
insertion sites were all negative for malignancy.
A month later, hysteroscopy with total surgical endo-
metrectomy confirmed the total absence of myometrial
involvement as the results came back with only complex
hyperplasia with atypia. The patient went on and receivedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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combined with six months of megestrol acetate and
leuprolide acetate.
Histological controls, six months then a year later,
obtained by hysteroscopy demonstrated the absence of
residual hyperplasia, atypia or malignancy. She resumed
menses after stopping megestrol and leuprolide.
She was scheduled for a control in May 2012 for a
hysteroscopic control, but she turned out to be preg-
nant. She was followed up by sonograms during her
pregnancy in order to rule out any recurrence. She had a
normal delivery in Paris, on February 2013. Actually the
patient is doing well with no evidence of disease.
Conclusions
This case exposes both a synchronous occurrence of
early-stage ovarian and endometrial carcinoma and the
conservative approach undertaken.
Coexistence of carcinoma of the ovary and endomet-
rium is not a rare event and has been reported in 5 to
10% of the cases from both origins [7], and as high as
25% in Walsh et al. [8], with no surgical or histological
proof of whether it is a synchronous occurrence or a
metastasis from one location to another. Synchronicity
has generally been contemplated more often based on
the demonstrated more favorable prognosis as well as
the similar pathologic appearance, while molecular studies
have been discordant. It has been suggested that embryo-
logically similar tissues, such as those of the female genital
tract, may be subject to a continuous or persistent
carcinogenic effect with an increased susceptibility [2],
possibly explaining synchronous or future development
of carcinoma in preserved organs, i.e. in conservative
treatment.
As a consequence, there is no established standard
treatment, as it varies between the institutions. Addition-
ally, synchronous tumors are frequently undiagnosed or
understaged [9]. This is mainly due to the limited value of
preoperative exams, but also to the fact that surgical
exploration by laparoscopy is not systematic in endo-
metrial cancer patients in order to verify the absence of
ovarian involvement. Nevertheless, intra-operative assess-
ment of ovarian pathology is fallible. Besides, the presence
of occult malignancy found in grossly normal-appearing
ovaries in the population of young women has already
been reported by various authors [10].
Our patient was different in that she was first diagnosed
with her ovarian tumor, her endometrial tumor being
asymptomatic, and due to her age and endometrioid hist-
ology, an endometrial curettage was advocated and carried
out to rule out endometrial malignancy.
Histologic features of these synchronous tumors are
generally uncommon and particular to this population.
These should elicit the suspicion of synchronous tumorswith a very low incidence of poorly differentiated or
grade 3 cancers, and a very low incidence of serous,
mucinous, or clear-cell histotype of ovarian cancer,
which otherwise would typically account for 70 to 80%
of tumors [9]. Synchronous tumors are generally much
more common in young patients less than 40 years old.
Survival rates are generally very high, with an estimated
recurrence rate at 5 years as low as 10% in women with
cancers limited to the uterus and ovaries according to
Zaino et al. [7]. The reason for the better than expected
survival for these patients is not intuitively obvious. Hence
it remains to date an observational pattern.
There are a number of studies reporting conservative
treatment for ovarian as well as endometrial cancer.
Firstly, the actual gold standard for treating epithelial
ovarian cancer (EOC) remains an adequate and complete
operative staging with the double objective of adapting the
therapeutic plan to the potential occult advanced disease
and of estimating the impact on overall prognosis. None-
theless, according to the 2007 guidelines of the American
College of Obstetrics and Gynecology (ACOG), fertility-
sparing surgery (FSS) for reproductive-age patients with
invasive EOC is recommended for highly or moderately
differentiated stage IA disease with favorable (non-clear-
cell) histology [11]. The European Society for Medical
Oncology (ESMO) also had a very similar statement in
2008 [12]. However, the level of evidence remains low,
due to the limited number of studies and the small pa-
tient samples [1]. In a recent study by Kashima et al.
[13], reproductive outcomes after FSS were found to be
favorable in a study including 18 patients with FIGO
stage IC epithelial ovarian cancer. Out of 10 patients
who attempted to conceive, 7 singleton pregnancies
were recorded for 5 women (50%) and all neonates were
delivered at term. Overall, when combining their results
with 7 other similar studies, namely Zanetta et al. [14],
Schilder et al. [15], Morice et al. [16], Borgfeldt et al.
[17], Park et al. [18], Kajiyama et al. [19], and Satoh et al.
[20], 125 of 502 women in the combined cohort became
pregnant, equivalent to a pregnancy rate of 24.9%.
As for endometrial cancer, the National Comprehensive
Cancer Network (NCCN) 2012 guidelines for uterine neo-
plasms affirm that although hysterectomy and appropriate
staging is the recommended treatment for endometrial
cancer, initial hormonal therapy can be considered for
young women with either atypical endometrial hyper-
plasia or grade I endometrial carcinoma, and who desire
fertility preservation [21]. However, their ultimate re-
currence rate remains high (around 44%) and the dis-
ease progression rate is around 5 to 6% [22]. Moreover,
the ACOG 2005 bulletin considers that progestational
agents may be a treatment option for selected candi-
dates, but that the disease will likely recur in most pa-
tients, which requires the need of continued histologic
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questions still remain unanswered, such as ideal proges-
tin regimen, duration of treatment, predictive criteria
for responsiveness, and need or timing for completion
hysterectomy after childbearing, to cite only few [24]. In
a multicenter Korean prospective study of hormonal
treatment, cure rate for endometrial carcinoma was 55%
and recurrence rate was 57% [25].
Conception is the ultimate goal of fertility-sparing
treatment and reproductive outcomes should be one of
our main concerns.
The majority of young patients with endometrial car-
cinomas tend to have coincident polycystic ovary syn-
drome or ovulatory disorders further hindering their
fertility. Contrariwise, in our case, the patient conceived
spontaneously. Furthermore, high dose progestin treat-
ment and repeated curettages could also lead to atrophy
and uterine synechia [16]. It is worthy to note that
endometrectomy was performed in our patient. This did
not alter the possibility of conceiving. No synechia were
noted on consecutive hysteroscopies. In the literature,
only two studies have proposed endometrectomy in the
management of endometrial carcinoma [26,27]. This may
reduce the bulk of the disease and accelerate the cure.
Patients should probably be counseled in order to attempt
immediate pregnancy after conservative treatment, and to
use assisted reproductive techniques (ART) more readily,
especially with the absence of current evidence that
ovulation induction agents are associated with a higher
risk of recurrence [15]. Most of the case reports and
retrospective series report abundant use of ART for
achieving pregnancy, mainly because of the short time
frame [17].
As for ovarian cancer, no relevant reproductive impair-
ment exists, with data concerning women who attempted
conception after FSS reporting a 66 to 100% success
rate [1].
It is worthy to note here that our patient received ad-
juvant chemotherapy along with progestin therapy, in
accordance with numerous studies demonstrating the
usefulness of adjuvant chemotherapy in increasing the
disease-free and overall survival rates in early-stage
ovarian cancers [28].
To our knowledge, despite the abundant literature on
synchronous ovarian and endometrial tumors, and the
numerous reports on conservative treatment conducted
for each one of these tumors, this is the first attempted
case of fertility sparing surgery for synchronous tumors,
and it resulted in a spontaneous pregnancy and normal
delivery, which further demonstrates its uniqueness.
Consent statement
Written informed consent was obtained from the patient
for publication of this case report.Abbreviations
ACOG: American college of obstetrics and gynecology; ART: Assisted
reproductive techniques; EOC: Epithelial ovarian cancer; ESMO: European
society for medical oncology; FSS: Fertility-sparing surgery; NCCN: National
comprehensive cancer network.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DA participated in the care of the patient and wrote the article. RR
participated in the care of the patient. JS and NK: participated in the writing
of article. GC validated content and form of the article. All authors read and
approved the final manuscript.
Author details
1Obstetrics and Gynecology, Hôtel Dieu de France University Hospital,
Saint Joseph University, Beirut, Lebanon. 2Institut Curie comprehensive
cancer center, Paris, France. 3Medical Oncology, Hôtel Dieu de France
University Hospital, Saint Joseph University, Beirut, Lebanon.
Received: 7 July 2013 Accepted: 20 August 2013
Published: 21 August 2013
References
1. Fotopoulou C, Braicu I, Sehouli J: Fertility-Sparing Surgery in Early Epithelial
Ovarian Cancer: a viable option? S.l. : Hindawi Publishing Corporation. 2012.
Obstet Gynecol Int 2012, Article ID 238061, 8 pages.
2. Nam JH, Park JY: Fertility-sparing surgery for young women with
early-stage epithelial ovarian cancer. Gynecol Obstet Invest. 2013,
76(1):14–24.
3. Gershenson DM: Fertility-sparing surgery for malignancies in women.
J Natl Cancer Inst Monogr 2005, 34:43–47.
4. Chiva L, Lapuente F, González-Cortijo L, Carballo L, García JF, Rojo A,
Gonzalez-Martín A: Sparing fertility in young patients with endometrial
cancer. Gynecol Oncol 2008, 111(Suppl 2):S101–S104.
5. Williams MG, Bandera EV, Demissie K, Rodríguez-Rodríguez L: Synchronous
primary ovarian and endometrial cancers: a population-based
assessment of survival. Obstet Gynecol 2009, 113(4):783–789.
6. Herrinton LJ, Voigt LF, Weiss NS, Beresford SA, Wingo PA: Risk factors for
synchronous primary endometrial and ovarian cancers. Ann Epidemiol
2001, 11(8):529–533.
7. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE: Simultaneously
detected endometrial and ovarian carcinomas- a prospective
clinicopathologic study of 74 cases: a gynecologic oncology group study.
Gynecol Oncol 2001, 83:355–362.
8. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I: Coexisting ovarian
malignancy in young women with endometrial cancer. Obstet Gynecol 2005,
106(4):693–699.
9. Signorelli M, Fruscio R, Lissoni AA, Pirovano C, Perego P, Mangioni C:
Synchronous early-stage endometrial and ovarian cancer. Int J Gynaecol
Obstet 2008, 102(1):34–38.
10. Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte MF, Bouchardy C,
Petignat P: Young patients with endometrial cancer: How many could
be eligible for fertility-sparing treatment. Gynecol Oncology 2009,
114(3):448–451.
11. American College of Obstetricians and Gynecologists: ACOG practice
bulletin: management of adnexal masses. Obstet Gynecol 2007,
110(1):201–214.
12. Aebi S, Castiglione M: Epithelial ovarian carcinoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol
2008, 19(Suppl 2):ii14–ii16.
13. Kashima K, Yahata T, Fujita K, Tanaka K: Outcomes of fertility-sparing
surgery for women of reproductive age with FIGO stage IC epithelial
ovarian cancer. Int J Gynaecol Obstet 2013, 121(1):53–55.
14. Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C:
Conservative surgery for stage I ovarian carcinoma in women of
childbearing age. Br J Obstet Gynaecol 1997, 104(9):1030–1035.
15. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ,
Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA,
Chu C, Stehman FB, van Nagell J: Outcome of reproductive age women with
Atallah et al. Journal of Ovarian Research 2013, 6:59 Page 4 of 4
http://www.ovarianresearch.com/content/6/1/59stage IA or IC invasive epithelial ovarian cancer treated with
fertility-sparing therapy. Gynecol Oncol 2002, 87(1):1–7.
16. Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, Duvillard P,
Lhommé C, Castaigne D, Classe JM, Bonnier P, GCCLCC and SFOG:
Conservative treatment in epithelial ovarian cancer: results of a
multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de
Lutte Contre le Cancer) and SFOG (Société Francaise d’Oncologie
Gynécologique). Hum Reprod 2005, 20(5):1379–1385.
17. Borgfeldt C, Iosif C, Måsbäck A: Fertility-sparing surgery and outcome in
fertile women with ovarian borderline tumors and epithelial invasive
ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2007, 134(1):110–114.
18. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes of
fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic
safety and reproductive outcomes. Gynecol Oncol 2008, 110(3):345–353.
19. Kajiyama H, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, Nagasaka T,
Kikkawa F: Fertility-sparing surgery in young women with invasive
epithelial ovarian cancer. Eur J Surg Oncol 2010, 36(4):404–408.
20. Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S,
Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D,
Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I,
Yoshikawa H: Outcomes of fertility-sparing surgery for stage I epithelial
ovarian cancer: a proposal for patient selection. J Clin Oncol 2010,
28(10):1727–1732.
21. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines 2012), Uterine
Neoplasms. [http://www.tri-kobe.org/nccn/guideline/gynecological/english/
uterine.pdf]
22. Martinez A, Poilblanc M, Ferron G, De Cuypere M, Jouve E, Querleu D:
Fertility-preserving surgical procedures, techniques. Best Pract Res Clin
Obstet Gynaecol 2012, 26(3):407–424.
23. American College of Obstetricians and Gynecologists: ACOG practice bulletin,
clinical management guidelines for obstetrician-gynecologists, number 65,
August 2005: management of endometrial cancer. Obstet Gynecol 2005,
106(2):413–425.
24. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH,
Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with
progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol
Cancer 2009, 19(6):1068–1073.
25. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T,
Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N,
Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T: Multicenter phase II
study of fertility-sparing treatment with medroxyprogesterone acetate for
endometrial carcinoma and atypical hyperplasia in young women. J Clin
Oncol 2007, 25(19):2798–2803.
26. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S:
Conservative treatment of early endometrial cancer: preliminary results
of a pilot study. Gynecol Oncol 2011, 120(1):43–46.
27. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G:
Conservative surgical management of stage IA endometrial carcinoma
for fertility preservation. Fertil Steril 2010, 93(4):1286–1289.
28. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V,
Williams C, Lissoni A, Bonazzi C, International Collaborative Ovarian
Neoplasm (ICON) collaborators: International Collaborative Ovarian
Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in
women with early-stage ovarian cancer. J Natl Cancer Inst 2003,
95(2):125–132.
doi:10.1186/1757-2215-6-59
Cite this article as: Atallah et al.: Simultaneous early ovarian and
endometrial cancer treated conservatively with spontaneous pregnancy.
Journal of Ovarian Research 2013 6:59.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
